Myomo Inc (MYO) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of Myomo Inc (NYSE:MYO) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.

Myomo (NYSE MYO) opened at 5.65 on Monday. The firm’s market capitalization is $34.39 million. The stock’s 50 day moving average price is $6.46 and its 200 day moving average price is $8.70. Myomo has a 52-week low of $5.12 and a 52-week high of $23.20.

Myomo (NYSE:MYO) last announced its earnings results on Monday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million during the quarter.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Equities Focus and is owned by of Equities Focus. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.equitiesfocus.com/2017/10/05/myomo-inc-myo-research-coverage-started-at-hc-wainwright.html.

A hedge fund recently bought a new stake in Myomo stock. Susquehanna International Group LLP bought a new position in shares of Myomo Inc (NYSE:MYO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,207 shares of the company’s stock, valued at approximately $187,000. Susquehanna International Group LLP owned about 1.53% of Myomo as of its most recent filing with the Securities and Exchange Commission (SEC).

About Myomo

Myomo, Inc is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke.

Receive News & Ratings for Myomo Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply